Form 4: Privia Health Director Receives Equity Grant Under Incentive Plan

Privia Health Group, Inc. Director Lance Berberian was granted 7,668 restricted stock units under the company's 2021 Omnibus Incentive Plan, vesting before the 2026 Annual Meeting.

Summary

• Lance Berberian, a Director of Privia Health Group, Inc. (PRVA), was granted 7,668 shares of common stock.
• These shares are Restricted Stock Units (RSUs) granted under the Issuer's 2021 Omnibus Incentive Plan.
• The RSUs will become fully vested on the day immediately preceding the date of the Company's 2026 Annual Meeting of Stockholders.
• The transaction date for the grant was July 15, 2025, with the filing signed on July 17, 2025.
• The acquisition price per share was $0, which is typical for RSU grants as a form of compensation.
• Following this transaction, Lance Berberian beneficially owns 7,668 shares directly.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive sign of alignment between management and shareholder interests, and a standard practice for executive compensation. It does not indicate any negative operational or financial news.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with shareholders, as the value of the grant is tied to the company's stock performance.
• The grant is part of the company's 2021 Omnibus Incentive Plan, indicating a structured approach to executive compensation and retention.

Future Outlook

The Restricted Stock Units granted to Director Lance Berberian are set to vest on the day immediately preceding the Company's 2026 Annual Meeting of Stockholders, indicating a future milestone for this equity compensation.

Industry Context

This transaction is a standard equity compensation practice within the healthcare services industry, where companies often use Restricted Stock Units to incentivize and retain key directors and executives, aligning their long-term interests with shareholder value creation.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to directors is a common practice in the U.S. healthcare industry, similar to compensation structures seen at companies like Teladoc Health (TDOC) or Amwell (AMWL), which also utilize equity incentives to align director interests with company performance.
• The vesting schedule, tied to a future annual meeting (2026), is typical for long-term incentive plans, providing a retention mechanism.
• The grant price of $0 is standard for RSU awards, as they represent a right to receive shares upon vesting, not a direct purchase.

Corporate Governance

Related Party Transactions

• This transaction involves a director (Lance Berberian) and the company (Privia Health Group, Inc.), representing a standard compensation grant under an approved incentive plan.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on general employees is indicated, though it reflects the company's compensation philosophy for key personnel.

Next Steps

• The Restricted Stock Units will vest on the day immediately preceding Privia Health Group, Inc.'s 2026 Annual Meeting of Stockholders.

Key Dates

Recommendation

Keywords

Privia Health Group, PRVA, SEC Form 4, Restricted Stock Units, RSU, Insider Trading, Director Compensation, Equity Grant, Omnibus Incentive Plan